T-cell therapy has been a game changer in the treatment of B-cell malignancies, although their manufacturing process is complex and needs lymphodepletion, thus limiting their use. Researchers from ...

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three ...

A new platform comprehensively profiles CAR T-cells during manufacturing, revealing phenotypic shifts. This allows for ...

Paulina Velasquez, MD, discusses the differences between T-cell receptor-based and chimeric antigen receptor T-cell therapies. Paulina Velasquez, MD, assistant faculty member, St. Jude Children’s ...

Chimeric antigen receptor (CAR) therapies utilize engineered receptors that are able to redirect immune cells to identify and destroy cancer cells that express a specific antigen. At present, CAR ...

A novel immunotherapy tool has emerged in the last ten years. T cells engineered to express chimeric antigen receptors, commonly known as CAR T cells, have demonstrated the ability to help ...

A group of researchers at Children's Hospital of Philadelphia (CHOP), in collaboration with Beam Therapeutics, have tested and developed an "off-the-shelf" chimeric antigen receptor T-cell (CART ...

A study investigates the reasons for decreasing remission rates for patients with non-Hodgkin lymphoma treated with chimeric antigen receptor-T cell therapy (CAR-T cell therapy). A study published ...

After infusion, CAR T cells leave the blood and travel to sites of tumor, where they identify and kill tumor cells. This can trigger extensive proliferation of CAR T cells and the release of tumor ...